Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- NNDM +1.7% (guidance, also - DM stockholders approve merger), BIGC +1.4% (reaffirms guidance, also names new CEO and exec chair)
Other news:
- CLW +4.8% (temporarily suspends ops at 2 faciltites due to Hurricane Helene)
- CDXS +3.2% (increases cash reserves; appoints new execs, including a new CFO)
- HROW +2.4% (announces the relaunch of TRIESENCE 40 mg/mL)
- FPI +1.9% (to divest $289 million of farmland to Farmland Reserve)
- XPER +1.9% (Xperi and Perceive completed Asset Purchase Agreement with Amazon.com (AMZN) Services)
- RNA +1.9% (announces FDA removed partial clinical hold on Delpacibart Etedesiran)
- ALDX +1.9% (resubmits NDA for Reproxalap)
- ABVX +1.7% (Reports Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance)
- LUV +1.5% (director acquires shares)